Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CRDF
CRDF
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRDF News
Cardiff Oncology Management Shakeup and Trial Update
Jan 28 2026
Benzinga
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations
Jan 27 2026
seekingalpha
Oncolytics Biotech Secures FDA Approval for First Pancreatic Cancer Immunotherapy
Dec 12 2025
Newsfilter
Cardiff Unveils Phase 1 Results of Onvensertib for Chronic Myelomonocytic Leukemia at ASH 2025
Dec 09 2025
NASDAQ.COM
Cardiff Oncology Presents Onvansertib Efficacy Data at ASH Meeting, 40% Patient Response
Dec 08 2025
Globenewswire
Cardiff Oncology Presents Clinical Data for Onvansertib in CMML at ASH Meeting
Dec 08 2025
Newsfilter
Cardiff Oncology to Present Novel Cancer Therapies at Sidoti Year-End Investor Conference
Dec 08 2025
Globenewswire
Healthcare Rally: Pulmonx, UHS, and X4 Experience After-Hours Gains Following Strategic Announcements
Oct 28 2025
NASDAQ.COM
AMD To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Aug 06 2025
Benzinga
Friday 8/1 Insider Buying Report: CRDF, MBIN
Aug 01 2025
NASDAQ.COM
Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?
Jul 30 2025
Benzinga
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Jul 30 2025
Benzinga
Cardiff Oncology Shares Slide Over 26% In Premarket Trading After Mixed Q2
Jul 30 2025
Benzinga
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Jul 30 2025
Benzinga
Cardiff Oncology To Announce New Data On Onvansertib In Colorectal Cancer Trial Tomorrow
Jul 28 2025
NASDAQ.COM
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
Jul 08 2025
Globenewswire
Show More News
